Skip to main content

Blueprint Medicines reports positive data

Blueprint Medicines Corp. (Nasdaq: BPMC) reported upbeat new data from an ongoing Phase 1 clinical trial of avapritinib to treat advanced systemic mastocytosis sending the stock price soaring $16.46 to close at $88.32.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.